Roche Hits Goal For Gazyva Expansion With Follicular Lymphoma Approval
This article was originally published in The Pink Sheet Daily
Sales for Roche’s Rituxan follow-on Gazyva grew substantially in 2015 to $128m, but still pale compared to AbbVie/J&J’s Imbruvica, which is approved for three blood cancers and brought in more than $1bn.
You may also be interested in...
FDA cleared Roche’s Rituxan follow-on GA101 in roughly six months, the same amount of time as an old-school priority review.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.